Envestnet Asset Management Inc. Has $26.82 Million Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Envestnet Asset Management Inc. raised its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 3.6% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 361,271 shares of the medical equipment provider’s stock after purchasing an additional 12,671 shares during the period. Envestnet Asset Management Inc. owned 0.15% of Hologic worth $26,824,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Cetera Investment Advisers lifted its holdings in Hologic by 188.9% in the first quarter. Cetera Investment Advisers now owns 20,464 shares of the medical equipment provider’s stock valued at $1,595,000 after buying an additional 13,380 shares during the period. Nordea Investment Management AB boosted its position in shares of Hologic by 1.3% in the 1st quarter. Nordea Investment Management AB now owns 1,507,743 shares of the medical equipment provider’s stock worth $116,797,000 after purchasing an additional 19,680 shares during the last quarter. Pinebridge Investments L.P. grew its stake in shares of Hologic by 39.8% during the fourth quarter. Pinebridge Investments L.P. now owns 397,251 shares of the medical equipment provider’s stock worth $28,384,000 after purchasing an additional 113,050 shares during the period. Clearbridge Investments LLC increased its holdings in Hologic by 51.4% in the first quarter. Clearbridge Investments LLC now owns 518,596 shares of the medical equipment provider’s stock valued at $40,430,000 after purchasing an additional 176,006 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in Hologic by 18.3% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,184,427 shares of the medical equipment provider’s stock valued at $170,297,000 after buying an additional 338,212 shares during the period. Institutional investors own 94.73% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. JPMorgan Chase & Co. upped their price target on Hologic from $91.00 to $95.00 and gave the company an “overweight” rating in a research note on Tuesday, July 30th. StockNews.com lowered shares of Hologic from a “strong-buy” rating to a “buy” rating in a report on Wednesday. Evercore ISI upped their price objective on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research report on Tuesday, July 30th. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 price objective on shares of Hologic in a research note on Tuesday, September 17th. Finally, Stephens reissued an “overweight” rating and issued a $92.00 target price on shares of Hologic in a research note on Tuesday, July 30th. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, Hologic currently has an average rating of “Moderate Buy” and a consensus price target of $87.60.

Insiders Place Their Bets

In other news, CEO Stephen P. Macmillan sold 3,672 shares of the business’s stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total transaction of $294,237.36. Following the transaction, the chief executive officer now directly owns 1,157,562 shares in the company, valued at approximately $92,755,443.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Christiana Stamoulis sold 9,039 shares of Hologic stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total transaction of $718,600.50. Following the completion of the transaction, the director now directly owns 45,472 shares in the company, valued at approximately $3,615,024. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Stephen P. Macmillan sold 3,672 shares of the stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total value of $294,237.36. Following the completion of the sale, the chief executive officer now owns 1,157,562 shares in the company, valued at approximately $92,755,443.06. The disclosure for this sale can be found here. Over the last three months, insiders have sold 18,280 shares of company stock valued at $1,469,973. 1.75% of the stock is currently owned by corporate insiders.

Hologic Stock Performance

Shares of HOLX opened at $81.39 on Friday. The stock has a market capitalization of $18.99 billion, a price-to-earnings ratio of 41.53, a PEG ratio of 2.53 and a beta of 0.98. Hologic, Inc. has a 12 month low of $64.02 and a 12 month high of $84.67. The firm has a fifty day simple moving average of $80.82 and a 200 day simple moving average of $77.12. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.04. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The company had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1 billion. During the same quarter last year, the company earned $0.93 EPS. Hologic’s revenue for the quarter was up 2.7% compared to the same quarter last year. Research analysts forecast that Hologic, Inc. will post 4.09 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.